Evidence map›Paper›PMID 34686672›Full record

ArticleNature communications2021

Engineering digitizer circuits for chemical and genetic screens in human cells.

Nicole M Wong, Elizabeth Frias, Frederic D Sigoillot, Justin H Letendre, Marc Hild, Wilson W Wong

Abstract read
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. High-content CRISPR screening.Nature reviews. Methods primers · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nicole M WongDepartment of Biomedical Engineering and Biological Design Center, Boston University, Boston, MA, 02215, USA.
Elizabeth FriasNovartis Institutes for BioMedical Research, Cambridge, MA, USA.
Frederic D SigoillotNovartis Institutes for BioMedical Research, Cambridge, MA, USA.ORCID 0000-0002-8695-4838
Justin H LetendreDepartment of Biomedical Engineering and Biological Design Center, Boston University, Boston, MA, 02215, USA.
Marc HildNovartis Institutes for BioMedical Research, Cambridge, MA, USA. marc.hild@novartis.com.ORCID 0000-0001-6039-2518
Wilson W WongDepartment of Biomedical Engineering and Biological Design Center, Boston University, Boston, MA, 02215, USA. wilwong@bu.edu.ORCID 0000-0001-8394-889X

Funding

Synthetic toolkit for precision gene expression control and signal processing in mammalian cellsR01EB029483 · NIBIB · HARVARD UNIVERSITY · PI Ahmad Samir Khalil · 2020 to 2026
$5.0M
Synthetically Reengineered T cells as the Next Generation of Smart Cancer TherapyDP2CA186574 · NCI · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI WONG, WILSON · 2013 to 2013
$2.5M
Advanced recombinase-based gene expression technology in mammalian cellsR01GM129011 · NIGMS · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI WONG, WILSON · 2019 to 2022
$1.5M
Advanced Recombinase Technology for Tissue Engineering ApplicationsF31HL149334 · NHLBI · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI LETENDRE, JUSTIN HENRY · 2019 to 2021
$88k
NCI NIH HHS DP2 CA186574NHLBI NIH HHS F31 HL149334NIBIB NIH HHS R01 EB029483NIGMS NIH HHS R01 GM129011
6 · The paper itself

Abstract

Cell-based transcriptional reporters are invaluable in high-throughput compound and CRISPR screens for identifying compounds or genes that can impact a pathway of interest. However, many transcriptional reporters have weak activities and transient responses. This can result in overlooking therapeutic targets and compounds that are difficult to detect, necessitating the resource-consuming process of running multiple screens at various timepoints. Here, we present RADAR, a digitizer circuit for amplifying reporter activity and retaining memory of pathway activation. Reporting on the AP-1 pathway, our circuit identifies compounds with known activity against PKC-related pathways and shows an enhanced dynamic range with improved sensitivity compared to a classical reporter in compound screens. In the first genome-wide pooled CRISPR screen for the AP-1 pathway, RADAR identifies canonical genes from the MAPK and PKC pathways, as well as non-canonical regulators. Thus, our scalable system highlights the benefit and versatility of using genetic circuits in large-scale cell-based screening.

Indexed as

CRISPR-Cas SystemsGenes, ReporterGenomicsHigh-Throughput Screening AssaysHumansPromoter Regions, GeneticSmall Molecule LibrariesTranscription FactorsSmall Molecule LibrariesTranscription Factors

Identifiers

PMID34686672
PMCPMC8536748

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.